[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630924":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":27,"responsibleParty":43,"collaborators":18,"id":45,"slug":18,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":18,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":18,"enrollmentInfo":52,"targetDuration":18,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel","EXPERIMENTAL",[12],"Drug: lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Iparomlimab and Tuvonralimab Injection: 5 mg\u002Fkg, q3w; Nab-Paclitaxel: 125 mg\u002Fm² on d1 and d8, q3w; Neoadjuvant therapy is administered for 4 cycles. The appropriate surgical timing will be determined by the physician based on the patient's condition, and surgery is scheduled for 4-6 weeks after the completion of neoadjuvant therapy.",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Zhansheng Jiang, Doctor","CONTACT","13512035574","18526812877@163.com",{"name":26,"role":22,"phone":18,"phoneExt":18,"email":18},"Chang Liu",[28],{"facility":5,"status":18,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Tianjin","Tianjin Municipality","300000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.17667,39.14222,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":23,"phoneExt":18,"email":24},"Zhansheng Jiang",{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100630924",false,"NCT07493993","Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Voluntarily understand and sign the informed consent form for this study.\n* Age ≥ 18 years, male or female.\n* Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition).\n* ECOG performance status of 0-2.\n* No prior treatment for esophageal squamous cell carcinoma.\n* Life expectancy ≥ 3 months.\n* Adequate function of major organs within 7 days before the first treatment (use of any blood components or cell growth factors within 14 days before enrollment is not permitted):Hemoglobin ≥ 90 g\u002FL; White blood cell count ≥ 3.5 × 10\\^9\u002FL; Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelets ≥ 80 × 10\\^9\u002FL; AST and ALT ≤ 2.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL\u002Fmin); Left ventricular ejection fraction (LVEF) ≥ 50%.\n* Fertile patients must agree to use reliable contraceptive methods with their partner during the trial and for at least 180 days after the last dose.\n\nExclusion Criteria:\n\n* Inability to comply with the study protocol or study procedures.\n* Presence of supraclavicular lymph node metastasis.\n* Obvious tumor invasion of organs adjacent to the esophageal lesion.\n* Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment.\n* Allergy or known hypersensitivity to the study drugs or their excipients.\n* Anticipated need for systemic corticosteroids or other immunosuppressive therapy during the study treatment period.\n* Active autoimmune disease requiring systemic treatment, or a history of autoimmune disease.\n* Positive HIV test; positive hepatitis B surface antigen with HBV-DNA \\> upper limit of normal; active hepatitis C virus (HCV) infection.\n* History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months before the first study drug administration; known severe varices on endoscopy within 3 months before the first study drug administration.\n* Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia that might interfere with the assessment and management of immune-related pulmonary toxicity.\n* Evidence of a significant bleeding tendency or other major coagulation disorders.\n* Severe cardiovascular or cerebrovascular disease.\n* Other malignancies within 5 years before enrollment, except for radically resected basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* History of allogeneic bone marrow transplantation or organ transplantation.\n* Patients considered by the investigator to be unsuitable for participation in this study.","ALL","18 Years",{"count":53,"type":54},26,"ESTIMATED","INTERVENTIONAL",[57],"PHASE2","Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1\u002FCTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.",[60],"ESCC",[62,63,64,60],"Iparomlimab and Tuvonralimab Injection","Nab-Paclitaxel","neoadjuvant therapy","NOT_YET_RECRUITING","2026-03-19",{"date":68,"type":69},"2026-03-27","ACTUAL",{"date":71,"type":54},"2026-06-01",{"date":73,"type":54},"2030-12-31",{"name":5,"class":6},1]